May contain unintended presence of milk derivatives, soy, cereals containing gluten (wheat), eggs, celery and mustard
Our study sheds light on these differences and the consistent benefits of semaglutide for women and men. The teams research included data from more than 1,000 HFpEF patients with and without type 2 diabetes
Dynamic and nuclear expression of PDGFR and IGF-1R in alveolar rhabdomyosarcoma
The beauty of IHM through MakoRx is that anyone can use this program, and you dont have to wait for a new plan year to start
2535% loss rates) 11:05 What efficacy estimate really means (race-track analogy) 13:28 Real-world view: treatment-regimen estimate (2023.7%) vs trial ideal 15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ 18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences) 21:02 Why the lower doses matter & who actually needs 30% weight loss 24:15 From just make the scale go down to quality of weight loss & body composition 28:05 Future focus: health, longevity, and peptides beyond hitting goal weight 30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & talk to your doctor 34:38 How retatrutide changes the next decade of obesity treatment conversations 37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook 40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review 45:20 Why small-molecule oral GLP-1s arent the same as injectable peptides 48:40 New topic: Indiana Safe Drug Act of 2025 and why Dave is concerned 51:02 Production caps, essentially a copy language & shifting power from prescribers to FDA 54:28 How the bill undermines personalization while ignoring real safety tools 57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting 59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors 1:02:05 Call to action: petition at otplinks.com & why patient voices matter 1:05:10 Change.org impact, media attention & centering the patient perspective 1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks Visit Our Sponsors
And thats the other big concern
